Printer Friendly

RECEPTOR LOGIC/SANOFI PASTEUR DEVELOP TCR FOR VACCINE TESTS.

Receptor Logic, Ltd., Austin, Texas, has announced a partnership with sanofi pasteur, the vaccines division of sanofi-aventis Group, to develop T Cell Receptor Mimics (TCRm(tm)) for the validation and testing of sanofi pasteur vaccines. Under a collaborative research and exclusive license agreement, Receptor Logic will create custom TCRm in support of sanofi pasteur's vaccine programs. Receptor Logic is funded and managed by life sciences venture firm, Emergent Technologies, Inc. (ETI).

Tony Taylor, Emergent Technologies Senior Vice President, Strategic Planning, stated, "Receptor Logic has developed a powerful tool called 'T Cell Receptor Mimics (TCRm(tm))' aimed at measuring immune presentation. Sanofi pasteur's interest in this novel approach supports the potential value of this technology towards the development of vaccines and drugs in the future."

About Receptor Logic, Ltd.

Receptor Logic, Ltd. is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T Cell Receptors in the immune system. These T Cell Receptor mimics (TCRm) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines.

In 2004 Receptor Logic, Ltd. was awarded $2 million from the Advanced Technology Program (ATP) of the National Institute of Standards & Technology (NIST) to fund development of a cancer profiling and immunotherapy platform targeting breast cancer. Receptor Logic, Ltd. is an Emergent Technologies Inc. (ETI) portfolio company, and ETI provides all management services. For more information, visit the company website www.receptorlogic.com.

About Emergent Technologies, Inc.

Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. ETI is pioneering a unique business approach the firm describes as invention capital.

In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each investment's intellectual property, the key asset to most technology-based start-up companies.

For more informaton, call 321/591-1508 or visit http://www.etibio.com.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Apr 1, 2008
Words:374
Previous Article:MYELOMA TREATMENT FOR OLDER PATIENTS SET FOR APPROVAL.
Next Article:REACHBIO/AXIOGENESIS TO DISTRIBUTE CELL-BASED PRODUCTS.
Topics:


Related Articles
Eisai, Sanofi Pasteur to Conclude Licensing Agreement for Vaccine Adjuvant E6020.
FDA approves first avian flu vaccine.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters